| Similar Articles |
|---|
 |
The Motley Fool
January 29, 2007
Brian Lawler |
No Dicey Results for Cubist The stock price may be down, but Cubist Pharmaceuticals is looking strong.   |
The Motley Fool
April 5, 2011
Cindy Johnson |
Cubist Pharmaceuticals Shares Popped: What You Need to Know Cubist Pharmaceuticals popped as much as 17% in intraday trading today after announcing a licensing agreement and the settlement of a patent dispute. |
The Motley Fool
October 20, 2006
Brian Lawler |
Cubist Paints a Greener Picture The pharmaceutical company is flush with cash and finally profitable. However, it might just be easier for Cubist to sell itself to a more substantial pharmaceutical company. Investors, take note. |
The Motley Fool
April 5, 2011
Brian Orelli |
Suit Settlement Sends Shares Skyrocketing Cubist Pharmaceuticals gets concessions as it settles its patent suit with Teva. |
The Motley Fool
December 5, 2006
Brian Lawler |
Cubist Finds an Asian Partner The smaller drug developer teams up with AstraZeneca to bring its antibiotic to worldwide markets. The best part of the deal is that Cubist retains the rights to Cubicin in Japan, which is by far the biggest market in all of Asia. Investors, take note. |
The Motley Fool
July 11, 2011 |
Cubist Pharmaceuticals Earnings Preview Cubist Pharmaceuticals will unveil its latest earnings on Thursday. |
The Motley Fool
July 20, 2006
Brian Lawler |
Cubist's Square Results The pharmaceutical company has a promising new drug, but little else in the pipeline. Investors, take note. |
The Motley Fool
January 26, 2005
Charly Travers |
Call Cubist in the Morning Strong drug sales provide a dose of good medicine for this pharmaceutical. |
The Motley Fool
April 8, 2005
Brian Gorman |
Cubist in Neutral Cubist Pharmaceuticals' pipeline may be why investors are unimpressed. |
The Motley Fool
July 3, 2008
Brian Lawler |
A Cubist Masterstroke Cubist Pharmaceuticals, until now a one-drug wonder, becomes a marketer of two compounds. |
The Motley Fool
August 20, 2011
Rex Moore |
2 Positive Signs for Cubist Pharmaceuticals Cubist Pharmaceuticals appears to be in good shape in terms of the intangible assets ratio and tangible book value. |
The Motley Fool
May 12, 2004
Charly Travers |
Cubist Addresses a Niche Market This small firm is developing antibiotics to meet a medical need. |
The Motley Fool
April 6, 2011
Brian Orelli |
Killing Bacteria With the Help of a Friend Optimer Pharmaceuticals has signed up Cubist Pharmaceuticals as a marketing partner for at least the next two years. |
The Motley Fool
October 27, 2004
Charly Travers |
Cubist's Growing Pains The pharmaceutical is going to have to work through some growing pains and make strides toward profitability before the performance of the stock will match the performance of its drug. |
The Motley Fool
December 28, 2007
Brian Lawler |
Cubist's Cheap Call Option As a Christmas Eve present to itself, Cubist Pharmaceuticals follows through on its October option to purchase Illumigen. |
The Motley Fool
June 28, 2005
Charly Travers |
Growth Around the Corner? Despite a thin pipeline, small biotech Cubist Pharmaceuticals is hoping to ride the wave of prosperity. Investors, take note. |
Chemistry World
December 11, 2014 |
Merck to buy antibiotics specialist Cubist Hours after the deal was announced, a US District Court invalidated several key patents for Cubist's top seller, Cubicin (daptomycin). |
The Motley Fool
September 30, 2011
David Williamson |
This Week in Biotech Biotech news about Array BioPharma, Human Genome Sciences, Pharmasset, and more. |
Pharmaceutical Executive
October 1, 2008
Michael Bonney |
Specialty Sales Gets No Resistance The author, a Cubist Pharmaceuticals CEO. has given his company a successful start and is now predicting the future of drug resistance. |
The Motley Fool
November 15, 2011
Selena Maranjian |
Make Money in Profitable Small Caps the Easy Way If you expect small companies to do well in coming years as the global economy recovers, the iShares S&P SmallCap 600 Index ETF could save you a lot of trouble. |
The Motley Fool
January 13, 2004
David Nierengarten |
Vicuron's Booster Shot With a new "super-tough" antibiotic, Vicuron's stock is super high. |
The Motley Fool
May 25, 2011
David Williamson |
Pay Attention to Shire The British ADHD medicine maker is busy making big moves. |
BusinessWeek
October 29, 2007
Catherine Arnst |
Superbugs: Where Are the Wonder Drugs? Antibiotics are losing the battle against superbugs, and drugmakers are slow to replenish the arsenal. |
The Motley Fool
May 29, 2009
Brian Orelli |
The Clouds Are Parting The Food and Drug Administration has scheduled an advisory committee meeting for Aug. 4 to get input on whether the agency should approve generic versions of ViroPharma's antibiotic, Vancocin. |
The Motley Fool
May 25, 2011
Brian Orelli |
Optimer's Upcoming FDA Decision: Memorable or Memorial? We'll know on Memorial Day, plus or minus a few days. |
The Motley Fool
October 20, 2006
Brian Lawler |
Lilly Pads Its Earnings Lilly reports third-quarter 2006 numbers and gobbles up Cialis. Investors, take note. |
The Motley Fool
March 25, 2009
Brian Orelli |
Wyeth: Now Approved to Kill More Bugs! Wyeth's antibiotic gets approved for another indication. |
On Wall Street
August 1, 2009 |
Five Questions with Robert Auer As founder of SBAuer Funds LLC, Robert Auer has been senior portfolio manager for the Auer Growth Fund since its inception in January 2008. Here, he speaks about fear, greed, and his family-owned fund. |
The Motley Fool
November 28, 2008
Brian Orelli |
The FDA's Killing Bug Killers Unfortunately for Johnson & Johnson and Swiss drugmaker Basilea Pharmaceutica, the FDA appears a little reluctant to take some of the data for the drugmakers' antibiotic ceftobiprole at face value. |
The Motley Fool
January 9, 2009
Brian Orelli |
Alnylam Holds Hands With a New Fella Is big pharma turning up its nose at RNAi drugs? |
